# OnCo record transcend-cll-004 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/transcend-cll-004/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "transcend-cll-004", "NCT03331198" ;
  schema:name "TRANSCEND CLL 004"@en ;
  schema:description "The study that brought CAR-T to CLL: one in five heavily pretreated patients achieved complete remission, most of them lasting."@en ;
  schema:url <https://onco.cc/trials/transcend-cll-004/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03331198> ;
  onco:status "positive" ;
  onco:phase "1/2" ;
  schema:startDate "2017-11-27" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:companies <https://onco.cc/companies/bms/> .